➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Colorcon
Express Scripts
Harvard Business School
Johnson and Johnson

Last Updated: September 19, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EDARBI

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Edarbi

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00362115 ↗ Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension Completed Takeda Phase 2 2006-05-01 The purpose of this study is to evaluate the safety, efficacy, and tolerability of azilsartan medoxomil, once daily (QD), in individuals with hypertension.
NCT00591253 ↗ Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension Completed Takeda Phase 3 2007-10-01 The purpose of this study is to evaluate the effectiveness and safety of azilsartan medoxomil compared to placebo, once daily (QD), in African-American participants with essential hypertension.
NCT00591266 ↗ Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension Completed Takeda Phase 3 2007-10-01 The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with amlodipine in treating individuals with essential hypertension, compared to treatment with amlodipine alone.
NCT00591578 ↗ Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension Completed Takeda Phase 3 2007-12-01 The purpose of this study is to compare the efficacy and safety of TAK-491 (azilsartan medoxomil), once daily (QD), to valsartan in participants with essential hypertension.
NCT00591773 ↗ Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension Completed Takeda Phase 3 2007-09-01 The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with chlorthalidone in treating individuals with essential hypertension, compared to treatment with chlorthalidone alone.
NCT00695955 ↗ One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension Completed Takeda Phase 3 2007-06-01 This purpose of this study is to evaluate the long-term safety and tolerability of azilsartan medoxomil in individuals with essential hypertension.
NCT00696241 ↗ Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension Completed Takeda Phase 3 2007-06-01 The purpose of this study is to determine the safety and efficacy of azilsartan medoxomil, once daily (QD), compared to placebo and olmesartan in participants with essential hypertension.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Edarbi

Condition Name

Condition Name for Edarbi
Intervention Trials
Hypertension 12
Essential Hypertension 2
Healthy Volunteer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Edarbi
Intervention Trials
Hypertension 13
Overweight 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Edarbi

Trials by Country

Trials by Country for Edarbi
Location Trials
United States 207
Mexico 16
China 15
Germany 9
Argentina 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Edarbi
Location Trials
California 9
Oklahoma 9
Ohio 9
North Carolina 9
Florida 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Edarbi

Clinical Trial Phase

Clinical Trial Phase for Edarbi
Clinical Trial Phase Trials
Phase 4 1
Phase 3 11
Phase 2 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Edarbi
Clinical Trial Phase Trials
Completed 12
Recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Edarbi

Sponsor Name

Sponsor Name for Edarbi
Sponsor Trials
Takeda 15
University of Chicago 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Edarbi
Sponsor Trials
Industry 15
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
AstraZeneca
McKesson
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.